T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections.
about
The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5'-triphosphate towards influenza A virus polymeraseBroad spectrum antiviral activity of favipiravir (T-705): protection from highly lethal inhalational Rift Valley FeverViral hemorrhagic fevers: advancing the level of treatmentT-705 (favipiravir) inhibition of arenavirus replication in cell culturePre-symptomatic diagnosis and treatment of filovirus diseasesInfluenza treatment and prophylaxis with neuraminidase inhibitors: a reviewNovel approaches and challenges to treatment of central nervous system viral infectionsProgress in the experimental therapy of severe arenaviral infectionsMonoclonal antibody produced in plants efficiently treats West Nile virus infection in miceThe Influenza Virus Polymerase Complex: An Update on Its Structure, Functions, and Significance for Antiviral Drug DesignNew small-molecule drug design strategies for fighting resistant influenza AInhibitors of foot and mouth disease virus targeting a novel pocket of the RNA-dependent RNA polymeraseA novel small molecule inhibitor of influenza A viruses that targets polymerase function and indirectly induces interferonFavipiravir (T-705) inhibits Junín virus infection and reduces mortality in a guinea pig model of Argentine hemorrhagic feverThe RNA template channel of the RNA-dependent RNA polymerase as a target for development of antiviral therapy of multiple genera within a virus familyInhibitors compounds of the flavivirus replication processProgress of small molecular inhibitors in the development of anti-influenza virus agents.In vitro activity of favipiravir and neuraminidase inhibitor combinations against oseltamivir-sensitive and oseltamivir-resistant pandemic influenza A (H1N1) virus.Antiviral therapy in seasonal influenza and 2009 H1N1 pandemic influenza: Korean experiences and perspectives.How I treat influenza in patients with hematologic malignancies.In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.Targeting pandemic influenza: a primer on influenza antivirals and drug resistance.Drugs in development for influenza.Antiviral strategies for pandemic and seasonal influenzaPerspective: emerging challenges in the treatment of influenza and parainfluenza in transplant patientsT-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitroEmerging antiviral strategies to interfere with influenza virus entry.Newer influenza antivirals, biotherapeutics and combinations.Advances in antivirals for non-influenza respiratory virus infections.Efficacy of T-705 (Favipiravir) in the Treatment of Infections with Lethal Severe Fever with Thrombocytopenia Syndrome VirusReverse genetics technology for Rift Valley fever virus: current and future applications for the development of therapeutics and vaccines.T-705 (favipiravir) activity against lethal H5N1 influenza A virusesInnate immune evasion strategies of influenza virusesHigh-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitorsIdentification of BPR3P0128 as an inhibitor of cap-snatching activities of influenza virus.Influenza A virus polymerase: structural insights into replication and host adaptation mechanismsArchitecture and regulation of negative-strand viral enzymatic machineryFavipiravir (T-705), a novel viral RNA polymerase inhibitor.Efficacy of favipiravir (T-705) and T-1106 pyrazine derivatives in phlebovirus disease modelsHuman Ebola virus infection in West Africa: a review of available therapeutic agents that target different steps of the life cycle of Ebola virus.
P2860
Q21089768-DF8D3A13-34C8-43BF-B624-AADA4B31EF5FQ21092271-8FC81DA7-FF72-4637-ABF7-ECAD75A2B9DCQ21245298-8CE2CF19-0C23-4E20-B7C2-956E70CFF6F5Q24633241-551AAD11-290E-4D24-BBCB-88DCDD87DD11Q26823831-22A4D90F-1441-4E8B-8D14-234DDEFC8C3AQ26860032-C52AD4B5-EF06-4E31-9174-CD8D1068135FQ26862449-19529044-6937-419C-B91A-C95B25A05A6EQ27024953-53ADCCB5-44CD-449D-9522-470616919609Q27490937-395D7694-E0C7-4C76-91F8-ECFF2D4AFA80Q28071809-A1915955-E7F3-4A3A-8B88-CDD7C1F8F1BFQ28080554-FE26B8F1-8018-414E-A1A3-D6DE05708369Q28476610-A14CCC4F-9A6C-41B3-B512-E79BD539E582Q28483298-B50B9ABD-8FC1-471D-9BFD-DB16139ACBFFQ28537976-E44A9E39-B2E1-46B7-A0A5-06E0C06090F9Q28544920-658DE355-3B38-4989-8733-B0468E81DB40Q29994474-3E413884-5E05-4D23-8E15-6DAA072AFD42Q30234943-6551A717-6A61-40F8-ABDF-717792965FD5Q30356466-3A697BAD-053B-4EC1-AD56-AE7B94DEDF2FQ30377702-71C75676-A2D5-481B-A2F2-6F68DE451F51Q30383456-D8A4F74C-E517-4873-B3CC-11E5CF0868C5Q30387420-274C361A-BAD3-4F15-9254-B5FCD405FD94Q30387832-830E262D-E353-4C76-A534-9DB5CAB6AE3EQ30391218-5F8D4C41-4E3A-49B4-AFB1-655ADD70BDC0Q30408116-9182437B-5400-4D40-B634-4C6D0E2701E7Q30412678-4E107608-5698-4244-BE0E-BB6345390147Q30426020-F914AD37-F7F4-46CD-B624-3BD24BC7253AQ30432421-F6F0DF89-28BF-4E25-A48F-D32F41642B58Q30456363-AFA120B7-D910-4430-ADDB-CFDAFA7FFD8EQ30457132-6FFD1731-8F26-48BF-851F-B8BDFD57F063Q33433096-BD603DD0-4573-4392-9D8C-2752D8410218Q33570326-4F565AD3-870D-4F81-AC33-EAE540869877Q33639979-0D278A3F-E851-451A-8DB6-1CE02761FA47Q33646273-810E069D-BFF6-4FFF-84A8-83F2D950776FQ33948876-3892D319-14E3-4E95-9F35-4B40736ABC5DQ34022729-68BBCA9C-2976-42C0-A71C-F0D0BC5B99BBQ34121115-4200107A-BC1E-4B4E-A563-46662EACDB9EQ34286309-6089B0E8-2028-41FF-9EC8-9E423C8DC6F8Q34374652-4C78C70B-9D2A-442E-A0EE-B16D73A5AA5DQ34432483-9F21E57D-DACC-410A-BBFC-A770A6342931Q34463780-68957AB7-B6E0-4133-83DE-A2FF4C09AB14
P2860
T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections.
description
2009 nî lūn-bûn
@nan
2009 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մարտին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
T-705 (favipiravir) and relate ...... itors of RNA viral infections.
@ast
T-705 (favipiravir) and relate ...... itors of RNA viral infections.
@en
type
label
T-705 (favipiravir) and relate ...... itors of RNA viral infections.
@ast
T-705 (favipiravir) and relate ...... itors of RNA viral infections.
@en
prefLabel
T-705 (favipiravir) and relate ...... itors of RNA viral infections.
@ast
T-705 (favipiravir) and relate ...... itors of RNA viral infections.
@en
P2093
P1433
P1476
T-705 (favipiravir) and relate ...... itors of RNA viral infections.
@en
P2093
Brian B Gowen
Dale L Barnard
Justin G Julander
Kazumi Takahashi
Kenichi Sakamoto
Kimiyasu Shiraki
Yousuke Furuta
P304
P356
10.1016/J.ANTIVIRAL.2009.02.198
P577
2009-03-06T00:00:00Z